

Review article

## How to deal with the side effects of long-term pharmacotherapy with aromatase inhibitors?

**Agnieszka Jagiełło-Gruszfeld**

Rafał Masztak Grochowski Hospital Sp. z o.o., Warsaw

For non-commercial use only

### Correspondence:

Agnieszka Jagiełło-Gruszfeld, MD, PhD  
Rafał Masztak Grochowski  
Hospital Sp. z o.o.  
ul. Grenadierów 51/59, 04-073 Warsaw  
e-mail: agnieszka.jagiellogruszfeld@gmail.com

### Received:

20.02.2024

### Accepted:

30.03.2024

DOI: 10.24292/01.OR.141301324

Copyright © Medical Education.

All rights reserved.

### ABSTRACT

Aromatase inhibitors are effective drugs used in adjuvant therapy of breast cancer. Their action is to reduce the level of oestrogens produced in adipose tissue in women in physiological or pharmacologically induced menopause. Nevertheless, long-term pharmacotherapy with aromatase inhibitors may lead to various side effects that may significantly affect the quality of life of patients. The following article presents the most common problems associated with aromatase inhibitor therapy and describes how to deal with these undesirable side effects.

**Key words:** breast cancer, adverse events, safety of treatment

## INTRODUCTION

Breast cancer is still the most frequently cancer diagnosed in women [1]. Despite the constant increase in incidence, improvement in survival rates for this cancer is observed. Therefore, more and more attention is paid to maintaining or improving the quality of life of patients and introducing methods of dealing with the side effects of treatment [2, 3].

This is particularly important in the case of long-term hormone therapy, which is recommended for patients diagnosed with hormone-dependent cancer. It is believed that this biological subtype is diagnosed in approximately 75–80% of cases [4]. Aromatase inhibitors (AI) have been shown to be more effective than the selective oestrogen receptor modulator (SERM), tamoxifen, both in neoadjuvant, adjuvant and metastatic breast cancer treatment [5, 6].

AI are used as an adjuvant therapy in hormone-dependent breast cancer according to the guidelines of the National Comprehensive Cancer Network (NCCN) and the European Society for Medical Oncology (ESMO) [7, 8]. According to the recommendations, AI are used longer, and the constant lack of oestrogen may affect a number of physiological functions, which leads to a deterioration of the quality of life of patients [6, 9]. Some patients may even decide to resign from continuing therapy, if they do not receive adequate support from an oncologist and information about the possibilities of reducing the disturbing symptoms. In such a case, the effectiveness of adjuvant treatment will be lower and a significant number of patients may experience a recurrence of cancer [10].

In randomized clinical trials, the rate of premature discontinuation of aromatase inhibitors was 8–24% [10]. However, treatment discontinuation rates in daily clinical practice ranged from 31% to 73%, suggesting that there may be important differences in how adjuvant treatment is delivered [10].

## AROMATASE INHIBITORS IN THE ADJUVANT TREATMENT OF BREAST CANCER

AI are undoubtedly an effective treatment for breast cancer in women in the postmenopausal period. Their action is to reduce the level of oestrogens produced in adipose tissue. Nevertheless, long-term AI pharmacotherapy may lead to various side effects that may significantly affect the quality of life of the patients. Two types of AI are available: the steroidal irreversible aromatase inactivator (exemestane) and the nonsteroidal reversible inhibitors (anastrozole and letrozole). A randomized phase III trial in

4,136 postmenopausal patients with hormone receptor-positive, node-positive early-stage breast cancer showed that letrozole was non-inferior to anastrozole in terms of disease-free survival, overall survival, and treatment safety. However, the trial was terminated prematurely due to shorter than expected disease-free survival [5]. A recently published meta-analysis showed similar effectiveness of all three AI [11]. However, the data comparing quality of life and treatment tolerability is limited.

It is believed that the incidence of skeletal side effects may be lower for exemestane than for the other two AI, but information on this subject is quite limited [5].

The most frequently described side effects of AI include vasomotor symptoms, muscle and joint pain, fatigue, hair thinning, and depression. However, bone loss is usually considered the most important [2, 3, 5].

The state of oestradiol deficiency causes increased bone remodelling and negative bone balance. This leads to loss of bone tissue, deterioration of the microstructure and bone fragility, predisposing to fractures. Fractures, in turn, are associated with increased morbidity, mortality and high socioeconomic burden [5].

Over recent years, many publications have appeared to provide guidance on how to effectively prevent and control AI-related adverse events.

## VASOMOTOR SYMPTOMS

Approximately 95% patients receiving adjuvant hormone therapy experience vasomotor symptoms. Although often ignored by medical staff, they cause anxiety for patients and are the most common reason for discontinuing hormone therapy [12]. Vasomotor symptoms are more frequently observed in patients receiving both goserelin and AI than in patients receiving AI alone. Vasomotor symptoms result from the altered function of the thermoregulatory centre contained in the hypothalamus, caused by hypoestrogenism [13] and are regulated by several neurotransmitters, mainly serotonin and norepinephrine [13]. Selective serotonin reuptake inhibitors (SSRIs) and norepinephrine reuptake inhibitors (SNRIs) may alleviate vasomotor symptoms [3, 13]. In particular, venlafaxine (SNRI) showed a reduction in the incidence of hot flashes in as many as 37–61% of patients (37.5 mg/24 h).

Anticonvulsants such as gabapentin and pregabalin showed similar effectiveness in reducing the incidence of vasomotor

symptoms, but had a poorer tolerability profile. Additionally, many patients benefit from non-pharmacological interventions, including acupuncture, cognitive-behavioural therapy (CBT) and physical activity.

### MUSCLE AND JOINT PAIN

Nearly 50% of patients receiving AI experience joint and muscle pain [14]. Administering another AI may be a helpful treatment option for patients suffering from joint pain. Duloxetine (SNRI) could be considered among potential pharmacological interventions. In patients with AI-related arthralgia, treatment with duloxetine led to a reduction in symptoms in approximately half of the patients [15].

Regarding other pharmacological interventions, a study on the effect of high-dose vitamin D supplementation was recently published and showed no significant effect on AI-related joint pain [16]. Glucosamine and chondroitin sulphate have also been evaluated in this context and have shown significant improvements in the incidence and severity of joint pain in more than half of patients [17]. In the prospective phase II study, where a combination of furosemide 20 mg and spironolactone 50 mg every other day was administered, as many as 84% of patients treated with AI showed a significant reduction in pain and joint stiffness, with improvement noticeable already in the first week of treatment [18].

The role of bisphosphonates in this respect was also assessed, and a lower incidence of joint pain was found when zoledronic acid was administered every 6 months at the end of the first year of treatment [3].

It has also been shown that aerobic exercise can reduce musculoskeletal pain. Additionally, acupuncture has shown long-term beneficial effects on AI-related pain.

### METABOLIC DISORDERS

Oestrogen deficiency is a key contributor to the development of metabolic disorders, including weight gain, diabetes, dyslipidaemia and non-alcoholic fatty liver disease (NAFLD). Approximately 21% of patients receiving AI have reported weight gain [19]. In subsequent stages, hypoestrogenism may lead to insulin resistance and increase the risk of type II diabetes [3]. NAFLD was observed in more than 1/3 of patients receiving AI treatment, likely due to an increased risk of dyslipidaemia [3].

Several studies have assessed the effectiveness of lifestyle interventions (including physical exercise and a healthy diet), in reducing the risk of metabolic disorders associated with hormone therapy. Weight loss and physical activity have been shown to reduce levels of pro-inflammatory cytokines and markers that are associated with breast cancer recurrence and metabolic comorbidities [3].

So far, pharmacological interventions (naltrexone, bupropion) have not been shown to be more effective in the treatment and/or prevention of metabolic disorders in patients receiving AI compared to interventions based only on lifestyle changes [20].

### OCULAR TOXICITY

The use of AI may lead to the dry eye syndrome due to the absence of the protective effect of oestrogens on the ocular surface [3]. This condition affects about 30% of patients.

It has been shown that androgen-based eye drops can improve the dry eye symptoms in up to 30% of patients [21].

### INSOMNIA

More than half of patients receiving adjuvant hormone therapy experience sleep disturbances, which may have a detrimental effect on their daily functioning and lead to mood disorders, concentration disorders and difficulties in focusing attention [3].

Pharmacological interventions (e.g. benzodiazepines) are usually recommended. However, the non-pharmacological approach (sleeping in a dark environment and using stress-reducing activities) is of fundamental importance.

Physical activity has also a positive impact on sleep. Acupuncture is an additional option that has been shown to be effective in reducing sleep disorders [22].

### FATIGUE

Fatigue is a common complaint among patients receiving AI, reported by over 80% of patients [3]. Despite the frequent occurrence of this symptom, data regarding the available intervention methods in this area is very limited. Fatigue is known to be associated with a sedentary lifestyle and obesity, so physical activity and a healthy diet are recommended. It has been reported that yoga or acupuncture can alleviate symptoms of fatigue [22].

## ALOPECIA

Alopecia is observed in as many as 9% of patients receiving tamoxifen and 2.5% of patients receiving AI [23]. A slight increase in hair loss is usually observed and usually occurs within the first year of treatment. Although this is not a common symptom, it is estimated that as many as 8% of patients discontinue treatment due to hair loss.

A daily topical 5% minoxidil solution has been shown to alleviate the occurrence of alopecia in 80% of patients receiving hormone therapy [23].

## GENITOURINARY SYNDROME OF MENOPAUSE

Hypoestrogenism occurring during menopause may lead to dysfunction of the vaginal epithelium and urinary tract, causing symptoms such as vaginal dryness, dyspareunia and painful urination. These symptoms occur together and are referred to as the genitourinary syndrome of menopause [24].

It is estimated that as many as 20% of patients receiving adjuvant hormone therapy discontinue treatment due to the occurrence of genitourinary syndrome of menopause [3].

Non-hormonal drugs should be administered as treatment. Vaginal suppositories with vitamin D, E showed an effect on the atrophy of the vaginal epithelium in patients receiving AI.

One can also use lidocaine vaginally, as well as lubricants and moisturizing agents.

Another potential option is intravaginal laser therapy, which can stimulate collagen synthesis and blood vessel formation [24].

In addition to physical symptoms, patients also complain of loss of libido and discomfort during a sexual intercourse. In such cases, cognitive-behavioural therapies are primarily recommended.

## OSTEOPENIA

Adjuvant hormone therapy for breast cancer causes bone mass loss and deteriorates bone metabolism [3, 5]. AI reduce circu-

lating oestrogen levels, thereby increasing bone turnover. The combination of goserelin and AI accelerates bone mass loss to a greater extent than the combination of goserelin and tamoxifen [5].

International guidelines recommend careful assessment of fracture risk in patients receiving adjuvant AI therapy by baseline densitometry.

Adopting a healthy lifestyle is also recommended, which should include quitting smoking, limiting alcohol consumption, taking up physical activity, planning meals rich in calcium and supplementing vitamin D [3]. If the risk of osteoporosis is identified, it is recommended to use antiresorptive drugs such as bisphosphonates (pyrophosphate analogues that accumulate in sites of bone remodelling) and denosumab (a monoclonal antibody that binds to the RANK receptor involved in osteoclast activation) [25]. It is worth noting that, in addition to their osteoprotective effects, antiresorptive agents may also have an impact on reducing the risk of bone metastases by modifying the bone microenvironment [3, 5].

## CONCLUSION

AI and tamoxifen are currently the basis of adjuvant treatment of hormone-dependent breast cancer. Despite its proven effectiveness, many women are afraid of this treatment due to its side effects. Therefore, it is of utmost importance to manage potential side effects of the therapy in a proactive way. Additionally, new therapy options have appeared in the adjuvant treatment of breast cancer (olaparib, inhibitors of cyclin-dependent kinases 4 and 6) in recent years, which may pose additional challenges in the proper management of side effects.

Toxicity occurring during adjuvant hormone therapy is often underestimated, but it has a significant impact on the quality of life of patients and may negatively affect compliance with therapeutic recommendations, and thus worsen the results of the breast cancer treatment.

## References

1. Wojciechowska U, Barańska K, Miklewska M et al. Cancer incidence and mortality in Poland in 2020. *Nowotwory. Journal of Oncology* 2023; 73(3): 129-45. <https://doi.org/10.5603/NJO.2023.0026>
2. Awan A, Esfahani K. Endocrine therapy for breast cancer in the primary care setting. *Curr Oncol.* 2018; 25(4): 285-91. <http://doi.org/10.3747/co.25.4139>.
3. Cucciniello L, Garufi G, Di Rienzo R et al. Estrogen deprivation effects of endocrine therapy in breast cancer patients: Incidence, management and outcome. *Cancer Treat Rev.* 2023; 120: 102624. <http://doi.org/10.1016/j.ctrv.2023.102624>.
4. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer. *Cochrane Database Syst Rev.* 2001; (1): CD000486. <http://doi.org/10.1002/14651858.CD000486>. Update in: *Cochrane Database Syst Rev.* 2008; (4): CD000486.
5. Chen S, Bo L, Lv D et al. Bone Safety Profile of Steroidal Aromatase Inhibitor in Comparison to Nonsteroidal Aromatase Inhibitors in Postmenopausal Women with Breast Cancer: A Network Meta-Analysis. *Breast Care (Basel).* 2022; 17(4): 391-402. <http://doi.org/10.1159/000523695>.
6. Symonds LK, Davidson NE. Are we there yet? Optimal duration of endocrine therapy in women with postmenopausal early-stage hormone receptor-positive breast cancer. *J Natl Cancer Inst.* 2023; 115(11): 1240-2. <http://doi.org/10.1093/jnci/djad111>.
7. Daly MB, Pal T, Maxwell KN et al. NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2024. *J Natl Compr Canc Netw.* 2023; 21(10): 1000-10. <http://doi.org/10.6004/jnccn.2023.0051>.
8. Loibl S, André F, Bachelot T et al.; ESMO Guidelines Committee. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. *Ann Oncol.* 2024; 35(2): 159-82. <http://doi.org/10.1016/j.annonc.2023.11.016>.
9. Gnant M, Fitzal F, Rinnerthaler G et al.; Austrian Breast and Colorectal Cancer Study Group. Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer. *N Engl J Med.* 2021; 385(5): 395-405. <http://doi.org/10.1056/NEJMoa2104162>.
10. Murphy CC, Bartholomew LK, Carpentier MY et al. Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. *Breast Cancer Res Treat.* 2012; 134(2): 459-78. <http://doi.org/10.1007/s10549-012-2114-5>.
11. Reinhorn D, Yerushalmi R, Moore A et al. Evolution in the risk of adverse events of adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer. *Breast Cancer Res Treat.* 2020; 182(2): 259-66. <http://doi.org/10.1007/s10549-020-05715-1>.
12. Lello S, Paris I, Cagnacci A et al. Vasomotor symptoms and management of women undergoing treatment for breast cancer: literature review with focus on the therapeutic potential of cytoplasmic pollen extract. *Gynecol Endocrinol.* 2023; 39(1): 2162035. <http://doi.org/10.1080/09513590.2022.2162035>.
13. Shams T, Firwana B, Habib F et al. SSRIs for hot flashes: a systematic review and meta-analysis of randomized trials. *J Gen Intern Med.* 2014; 29(1): 204-13. <http://doi.org/10.1007/s11606-013-2535-9>.
14. Hyder T, Marino CC, Ahmad S et al. Aromatase Inhibitor-Associated Musculoskeletal Syndrome: Understanding Mechanisms and Management. *Front Endocrinol (Lausanne).* 2021; 12: 713700. <http://doi.org/10.3389/fendo.2021.713700>.
15. Henry NL, Unger JM, Schott AF et al. Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202. *J Clin Oncol.* 2018; 36(4): 326-32. <http://doi.org/10.1200/JCO.2017.74.6651>.
16. Niravath P, Hilsebeck SG, Wang T et al. Randomized controlled trial of high-dose versus standard-dose vitamin D3 for prevention of aromatase inhibitor-induced arthralgia. *Breast Cancer Res Treat.* 2019; 177(2): 427-35. <http://doi.org/10.1007/s10549-019-05319-4>.
17. Greenlee H, Crew KD, Shao T et al. Phase II study of glucosamine with chondroitin on aromatase inhibitor-associated joint symptoms in women with breast cancer. *Support Care Cancer.* 2013; 21(4): 1077-87. <http://doi.org/10.1007/s00520-012-1628-z>.
18. Alhanafy AM, Labeeb A, Khalil A. The Role of Diuretics in Treatment of Aromatase Inhibitors Induced Musculoskeletal Symptoms in Women with Non-Metastatic Breast Cancer. *Asian Pac J Cancer Prev.* 2018; 19(12): 3525-31. <http://doi.org/10.31557/APJCP.2018.19.12.3525>.
19. Lambert LK, Balneaves LG, Howard AF et al. Patient-reported factors associated with adherence to adjuvant endocrine therapy after breast cancer: an integrative review. *Breast Cancer Res Treat.* 2018; 167(3): 615-33. <http://doi.org/10.1007/s10549-017-4561-5>.
20. Cho AR, Choi WJ, Kwon YJ et al. Mediterranean Diet and Naltrexone/Bupropion Treatment for Weight Loss in Overweight and Obese Breast Cancer Survivors and Non-Cancer Participants: A Pilot Randomized Controlled Trial. *Diabetes Metab Syndr Obes.* 2020; 13: 3325-35. <http://doi.org/10.2147/DMSO.S269237>.
21. Wang L, Deng Y. The applications of androgen in the treatment of dry eye disease: a systematic review of clinical studies. *Endocr J.* 2020; 67(9): 893-902. <http://doi.org/10.1507/endocrj.EJ20-0178>.
22. Hershman DL, Unger JM, Greenlee H et al. Comparison of Acupuncture vs Sham Acupuncture or Waiting List Control in the Treatment of Aromatase Inhibitor-Related Joint Pain: A Randomized Clinical Trial. *JAMA Netw Open.* 2022; 5(11): e2241720. <http://doi.org/10.1001/jamanetworkopen.2022.41720>.
23. Freitas-Martinez A, Shapiro J, Chan D et al. Endocrine Therapy-Induced Alopecia in Patients with Breast Cancer. *JAMA Dermatol.* 2018; 154(6): 670-5. <http://doi.org/10.1001/jamadermatol.2018.0454>.
24. Moskalewicz A, Di Tomaso A, Kachura JJ et al. Gynecologic Symptoms among Hormone Receptor-Positive Breast Cancer Patients on Oral Endocrine Therapy: A Cross-Sectional Study. *Curr Oncol.* 2022; 29(3): 1813-27. <http://doi.org/10.3390/curroncol29030149>.
25. Coleman R, Hadji P, Body JJ et al.; ESMO Guidelines Committee. Bone health in cancer: ESMO Clinical Practice Guidelines. *Ann Oncol.* 2020; 31(12): 1650-63. <http://doi.org/10.1016/j.annonc.2020.07.019>.

For non-commercial use only

**Conflict of interests:**

None.

**Financial support:**

None.

**Ethics:**

The authors had full access to the data and take full responsibility for its integrity. All authors have read and agreed with the content of the manuscript as written. The paper complies with the Helsinki Declaration, EU Directives and harmonized requirements for biomedical journals.